Netramark signs contract with AlgoTherapeutix

Mr. Josh Spiegel reports NETRAMARK SIGNS CONTRACT WITH ALGOTX TO ENHANCE CLINICAL TRIAL DESIGN FOR ATX01 Netramark Holdings Inc. and AlgoTherapeutix SAS, a clinical-stage biotechnology company developing first-in-class therapies for chemotherapy-induced peripheral neuropathy, have entered into an agreement. Under this agreement, Netramark will deploy its NetraAI platform to analyze patient-level data from AlgoTx's ATX01 program. NetraAI's unique technology will enable deep exploration of drug and placebo response variables, identification of responder personas, and delivery of enrichment strategies to inform the design of future ATX01 trials. AlgoTx has established itself as a forward-thinking innovator committed to improving the lives of patients suffering from CIPN with non-opioid solutions. The company's decision to partner with Netramark underscores its dedication to leveraging cutting-edge technologies to optimize trial design, with the goal of accelerating development timelines. NetraAI's unique methodology goes beyond traditional artificial intelligence and machine learning tools by identifying and characterizing highly specific patient personas, enabling sponsors like AlgoTx to reduce placebo response, improve signal detection and enrich trial populations with the most responsive patients -- all critical factors in driving trial success. "AlgoTx is a leader in bringing innovation to complex pain treatments," said Josh Spiegel, president of Netramark. "Their decision to partner with us reflects the growing recognition that explainable, precision AI can unlock value from clinical data sets that conventional approaches overlook. We look forward to supporting their team in seeking to enhance trial design and accelerate progress for patients in need." "At AlgoTx, we are committed to integrating innovation at every stage of development to unlock new therapeutic possibilities for patients living with CIPN," said Stephane Thiroloix, founder and chairman of the board of directors. "This agreement reflects our commitment to applying best-in-class innovation at every stage of our pipeline to ensure we bring transformative therapies to patients as efficiently as possible." Netramark's work will include the development of customized AI models and interactive tools that allow the AlgoTx team to test hypotheses, vary clinical significance thresholds and precisely characterize patient subpopulations. The collaboration will focus on generating validated, explainable and regulator-ready insights to optimize future studies. About Netramark Holdings Inc. Netramark is a company focused on being a leader in the development of generative artificial intelligence/machine learning solutions targeted at the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows Netramark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activate traditional AI/ML methods. The result is that Netramark can work with much smaller data sets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. We seek Safe Harbor.